Table 1.
Summary of the clinical trials of the drugs that inhibit MDM2.
| Drug | Phase | Status (Result) | Sponsor | Number of participants | Reference or Clinicaltrials.gov identifier |
|---|---|---|---|---|---|
| RG7112 | 1 | Completed | Hoffmann-La Roche | 116 | NCT00623870 |
| Idasanutlin | 1/2 | Terminated | Hoffmann-La Roche | 24 | NCT03850535 |
| Idasanutlin | 3 | Terminated | Hoffmann-La Roche | 447 | NCT02545283 |
| Idasanutlin | 1 | Completed | Hoffmann-La Roche | 88 | NCT02670044 |
| Idasanutlin | 1/2 | Recruiting | Hoffmann-La Roche | 220 | NCT04029688 |
| AMG-232 | 1 | Recruiting | National Cancer Institute (NCI) | 34 | NCT04190550 |
| APG-115 | 1 | Recruiting | Ascentage Pharma Group Inc. | 90 | NCT04275518 |
| Milademetan | 1 | Completed | Daiichi Sankyo Co., Ltd. | 14 | NCT03671564 |
| Milademetan | 1 | Recruiting | Daiichi Sankyo, Inc. | 156 | NCT03552029 |
| Milademetan | 1/2 | Recruiting | M.D. Anderson Cancer Center | 58 | NCT03634228 |
| Milademetan | 1 | Active, not recruiting | Daiichi Sankyo, Inc. | 200 | NCT02319369 |